Published in Drug Week, January 19th, 2007
Women sometimes discontinue therapy, or avoid it altogether, because of anxiety about the effects of these drugs. Unfortunately, some patients will not respond to the drug, and will experience the often-devastating side effects in vain. Now a report from the 29th Annual San Antonio Breast Cancer Symposium suggests that there may be a straightforward way to predict who will respond to anthracycline drugs, based on a commonly measured tumor marker.
Multiple clinical trials...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.